New drug cocktail shows promise for aggressive breast cancer

NCT ID NCT03368729

First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study tests a combination of two drugs, niraparib and trastuzumab, in people with metastatic HER2-positive breast cancer. The goal is to see if the combo is safe and can shrink tumors or slow the disease. About 46 women with advanced cancer that has spread will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Montefiore

    The Bronx, New York, 10461, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27599, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Washington-

    Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.